A5024441483- Virus-based gene therapy research
- interferon and immune responses
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- RNA Interference and Gene Delivery
- Animal Virus Infections Studies
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Herpesvirus Infections and Treatments
- RNA modifications and cancer
- Advanced biosensing and bioanalysis techniques
- CAR-T cell therapy research
- RNA Research and Splicing
- Cell death mechanisms and regulation
- Circular RNAs in diseases
Siberian Branch of the Russian Academy of Sciences
2021-2024
Institute of Chemical Biology and Fundamental Medicine
2021-2024
Virotherapy is one of the perspective technologies in treatment malignant neoplasms. Previously, we have developed oncolytic vaccinia virus VV-GMCSF-Lact and its high cytotoxic activity antitumor efficacy against glioma was shown. In this work, using immortalized patient-derived cells with different sensitivity to VV-GMCSF-Lact, evaluated effect chemotherapy agents. Additionally, studied combination temozolomide which most preferred drug for treatment. Experimental results indicate that...
Glioblastoma is one of the most aggressive brain tumors. Given poor prognosis this disease, novel methods for glioblastoma treatment are needed. Virotherapy actively developed approaches cancer therapy today. VV-GMCSF-Lact a recombinant vaccinia virus with deletions viral thymidine kinase and growth factor genes insertions granulocyte-macrophage colony-stimulating oncotoxic protein lactaptin genes. The has high cytotoxic activity against human cells various histogenesis antitumor efficacy...
Glioblastoma is one of the most malignant and aggressive tumors central nervous system. Despite standard therapy consisting maximal surgical resection chemo- radiotherapy, median survival patients with this diagnosis about 15 months. Oncolytic virus promising areas for treatment neoplasms. In review, we have focused on emphasizing recent achievements in virotherapy, both as a monotherapy combination other therapeutic schemes to improve rate quality life among glioblastoma.
Glioma is the most common and heterogeneous primary brain tumor. The development of a new relevant preclinical models necessary. As research moves from cultures adherent gliomas to more model, neurospheres, it necessary understand changes that cells undergo at transcriptome level. In present work, we used three patient-derived two immortalized glioblastomas, while their cultivation was carried out under culture neurosphere (NS) conditions. When comparing transcriptomes monolayer (ML) NS cell...
The resistance of glioblastoma to existing therapies puts limits on quality-of-life improvements and patient survival with a diagnosis. development new effective is based knowledge about the mechanisms governing tumor therapeutic agents. Virotherapy one most actively developing approaches treatment malignant neoplasms: in particular. Previously, we demonstrated that recombinant vaccinia virus VV-GMCSF-Lact exhibits
Background . One of the promising methods treating tumors is virotherapy, which based on direct lysis cancer cells by a virus and virus-mediated antitumor immune response body. For recombinant vaccinia strain VVGMCSF-Lact, producing human GMCSF oncotoxic protein lactaptin, cytotoxic effects were shown in experiments vitro vivo, respectively, when using adhesive cultures U-87 MG glioblastoma cells. 3D are more relevant tumor model than models, as they fully reflect realistic scenario...
Oncolytic virotherapy is a promising approach for cancer treatment. However, when introduced into the body, virus provokes production of virus-neutralizing antibodies, which can reduce its antitumor effect. To shield viruses from immune system, aptamers that cover membrane viral particle are used. Aptamers specifically bind to JX-594 strain vaccinia were developed earlier. parameters binding recombinant VV-GMCSF-Lact, based on LIVP virus, may differ due different repertoire antigenic...
When studying the action of oncolytic virus VV-GMCSF-Lact, including contribution GMCSF to oncotoxic effect drug, a pronounced immune response due both and influence was observed on model subcutaneously transplanted GL-261 murine glioma. Immune cell populations animals treated with rhGMCSF rmGMCSF were characterized in comparison from control groups.
Oncolytic virotherapy is a rapidly evolving approach that aims to selectively kill cancer cells. We designed promising recombinant vaccinia virus, VV-GMCSF-Lact, for the treatment of solid tumors, including glioma. assessed how VV-GMCSF-Lact affects human cells using immortalized and patient-derived glioma cultures non-malignant brain cell culture. Studying transcriptome changes in 12 h or 24 after infection, we detected common activation histone genes. Additionally, genes associated with...
It has been shown that under the action VV-GMCSF-Lact, death of glioblastoma cells occurs mainly through apoptotic pathway. When analyzing complexes Smac protein with apoptosis inhibitor XIAP in human cells, it was found most sensitive to level increased after incubation virus. At same time, overall higher more resistant cells.